FrancophonIA/ELRC3.0 huggingface dataset:
English: Treatment with lutetium (177Lu) oxodotreotide is not recommended for patients with severe heart failure defined as class III or class IV in the NYHA classification therefore, the benefit risk for these patients will always need to be weighed carefully.
Croatian: Liječenje lutecijevim (177Lu) oksodotreotidom ne preporučuje se u bolesnika s teškim zatajenjem srca klase III ili klase IV prema NYHA klasifikaciji pa je stoga uvijek potrebno pažljivo procijeniti omjer koristi i rizika za te bolesnike.
English: In case hyperkalaemia symptoms develop during LysaKare infusion, appropriate corrective measures must be taken.
Croatian: U slučaju razvoja simptoma hiperkalijemije tijekom infuzije lijeka LysaKare, potrebno je poduzeti odgovarajuće mjere kako bi se hiperkalijemija korigirala.
English: Arginine and lysine undergo glomerular filtration and, via competition, interfere with renal resorption of lutetium (177Lu) oxodotreotide, reducing the radiation dose delivered to the kidney.
Croatian: Mehanizam djelovanja Arginin i lizin podliježu glomerularnoj filtraciji i putem kompeticije interferiraju s bubrežnom resorpcijom lutecijeva (177Lu) oksodotreotida smanjujući dozu zračenja koja se isporučuje bubregu.
English: If you receive more LysaKare than you should LysaKare will be given in a controlled clinical setting and is provided as a single dose bag.
Croatian: LysaKare će se davati u kontroliranom kliničkom okruženju te se isporučuje kao vrećica koja sadrži jednu dozu.
English: LysaKare is indicated for reduction of renal radiation exposure during peptide-receptor radionuclide therapy (PRRT) with lutetium (177Lu) oxodotreotide in adults.
Croatian: LysaKare je namijenjen smanjenju izlaganja bubrega zračenju tijekom radionuklidne terapije usmjerene na peptidne receptore (engl. peptide-receptor radionuclide therapy, PRRT) s lutecijevim (177Lu) oksodotreotidom u odraslih.
English: Patiens with hepatic impairment
Croatian: Bolesnici s oštećenjem jetre
English: The adverse reactions are listed according to the frequency.
Croatian: Nuspojave su navedene u skladu s učestalošću.
English: Treatment with lutetium (177Lu) oxodotreotide is not recommended for patients with renal function between 30 and 50 mL/min therefore, the benefit risk for these patients will always need to be weighed carefully, which should include consideration of an increased risk for transient hyperkalaemia in these patients (see section 4.4).
Croatian: Liječenje lutecijevim (177Lu) oksodotreotidom ne preporučuje se u bolesnika s bubrežnom funkcijom između 30 i 50 ml/min pa je stoga omjer koristi i rizika za te bolesnike uvijek potrebno pažljivo procijeniti što uključuje razmatranje povećanog rizika od prolazne hiperkalijemije u tih bolesnika (vidjeti dio 4.4).
English: The use of arginine and lysine has not been studied in patients with severe hepatic impairment.
Croatian: Primjena arginina i lizina nije ispitivana u bolesnika s teškim oštećenjem jetre.
English: Based on a study with 30 g arginine infused over 30 minutes, plasma elimination of amino acids follows at least a biphasic or triphasic decline, with levels returning to baseline within 6 hours post-dose.
Croatian: minuta, plazmatska eliminacija aminokiseline slijedi najmanje bifazični ili trifazični pad s razinama koje se vraćaju na početne vrijednosti unutar 6 sati nakon doze.
English: LysaKare is indicated for administration with PRRT with lutetium (177Lu) oxodotreotide therefore, it should only be administered by a health care provider experienced in the use of PRRT.
Croatian: LysaKare je namijenjen za primjenu PRRT-a s lutecijevim oksodotreotidom (177Lu) te ga treba primjenjivati samo zdravstveni radnik iskusan u primjeni PRRT-a.
English: PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGING Polyvinyl chloride (PVC) infusion bag
Croatian: Infuzijska vrećica od polivinilklorida (PVC)
English: Driving and using machines It is considered unlikely that LysaKare will affect your ability to drive or to use machines.
Croatian: Nije vjerojatno da će LysaKare utjecati na vašu sposobnost upravljanja vozilima i strojevima.
English: Breast-feeding should be avoided during treatment with lutetium (177Lu) oxodotreotide.
Croatian: Potrebno je izbjegavati dojenje tijekom liječenja lutecijevim (177Lu) oksodotreotidom.
English: Metabolism and nutrition disorders Hyperkalaemia
Croatian: Poremećaji metabolizma i prehrane
English: NAME OF THE MEDICINAL PRODUCT LysaKare 25 g/25 g solution for infusion L-arginine hydrochloride/L-lysine hydrochloride
Croatian: LysaKare 25 g/25 g otopina za infuziju L-argininklorid/L-lizinklorid
English: OTHER SPECIAL WARNING(S), IF NECESSARY Do not reconnect partially used bags.
Croatian: DRUGO(A) POSEBNO(A) UPOZORENJE(A), AKO JE POTREBNO
English: Animal studies are insufficient with respect to reproductive toxicity (see section 5.3).
Croatian: Ispitivanja na životinjama su nedostatna za konačan zaključak u pogledu reproduktivne toksičnosti
English: Treatment with lutetium (177Lu) oxodotreotide is not recommended for patients with renal function between 30 and 50 mL/min therefore, the benefit risk for these patients will always need to be weighed carefully, which should include consideration of an increased risk for transient hyperkalemia in these patients.
Croatian: Liječenje lutecijevim (177Lu) oksodotreotidom ne preporučuje se u bolesnika s klirensom kreatinina između 30 i 50 ml/min pa je stoga uvije potrebno pažljivo procijeniti omjer koristi i rizika za ove bolesnika uključujući razmatranje povišenog rizika od prolazne hiperkalijemije u tih bolesnika.
English: Very common (may affect more than 1 in 10 people): • nausea (feeling sick) and vomiting
Croatian: Vrlo često (mogu se javiti u više od 1 na 10 osoba):
English: Each infusion bag contains 1 L LysaKare of solution.
Croatian: Jedna infuzijska vrećica sadrži 1 litar otopine LysaKare.
English: How to store LysaKare 6.
Croatian: Moguće nuspojave 5. Kako čuvati LysaKare
English: NAME OF THE MEDICINAL PRODUCT LysaKare 25 g/25 g solution for infusion
Croatian: LysaKare 25 g/25 g otopina za infuziju
English: The patient should be monitored closely for signs and symptoms of hyperkalaemia, e.g. dyspnoea, weakness, numbness, chest pain and cardiac manifestations (conduction abnormalities and cardiac arrhythmias).
Croatian: slabost, utrnulost, bol u prsima, te srčane manifestacije (provodne abnormalnosti srca te srčane aritmije).
English: What LysaKare contains - The active substances are arginine and lysine.
Croatian: - Djelatne tvari su arginin i lizin.
English: There are very limited data on the safety profile of arginine and lysine solution for infusion without concomitant administration of PRRT, which also includes the use of anti-emetics as pre-medication and often the concomitant use of short acting somatostatin analogues.
Croatian: PRRT-a što također uključuje uporabu antiemetika kao premedikacije te često i istodobnu primjenu kratkodjelujućih analoga somatostatina.
English: The use of arginine and lysine has not been specifically studied in patients with renal impairment.
Croatian: Bolesnici s oštećenjem bubrega Primjena arginina i lizina nije specifično proučavana u bolesnika s oštećenjem bubrega.
English: Gastrointestinal disorders Nausea
Croatian: Poremećaji probavnog sustava Mučnina
English: QUALITATIVE AND QUANTITATIVE COMPOSITION One 1,000 mL bag contains 25 g of L-arginine hydrochloride and 25 g of L-lysine hydrochloride.
Croatian: Jedna vrećica s 1000 ml sadrži 25 g L-argininklorida i 25 g L-lizinklorida.
English: Each infusion bag contains 25 g of L-arginine hydrochloride and 25 g of L-lysine hydrochloride.
Croatian: Jedna infuzijska vrećica sadrži 25 g L-argininklorida te 25 g L-lizinklorida.
English: STATEMENT OF ACTIVE SUBSTANCE(S) Each bag of 1,000 mL contains 25 g of L-arginine hydrochloride and 25 g of L-lysine hydrochloride.
Croatian: Jedna vrećica od 1000 ml sadrži 25 g L-argininklorida i 25 g L-lizinklorida.
English: • Hypersensitivity to the active substances or to any of the excipients listed in section 6.1.
Croatian: • Preosjetljivost na djelatne tvari ili ili neku od pomoćnih tvari navedenih u dijelu 6.1. • Postojeća klinički značajna hiperkalijemija ako nije odgovorajuće korigirana prije početka infuzije lijeka LysaKare (vidjeti dio 4.4).
English: Manufacturer Laboratoire Bioluz Zone Industrielle de Jalday 64500 Saint Jean de Luz France
Croatian: Laboratoire Bioluz Zone Industrielle de Jalday
English: oxodotreotide and dose limiting if amino acids are not administered to reduce renal uptake and retention.
Croatian: Kod primjene lutecijevog (177Lu) oksodotreotida bubrezi su kritični organi s obzirom na njegovu toksičnosti te posljedično dovode do ograničavanja doze ako se za smanjenje bubrežnog unosa i retencije ne primjenjuju aminokiseline.
English: B. PACKAGE LEAFLET
Croatian: Tablica 1 Nuspojave
English: Adverse drug reaction
Croatian: UČINKOVITU PRIMJENU LIJEKA
English: PHARMACEUTICAL FORM AND CONTENTS Solution for infusion
Croatian: OBLIK I SADRŽAJ
English: This summary was last updated in July 2015.
Croatian: Sažetak je posljednji put ažuriran u srpnju 2015.
English: In the future, if the animals are exposed to the virus the immune system will be able to respond more quickly.
Croatian: Ako životinje u budućnosti budu izložene tim infekcijama, imunosni sustav moći će brže reagirati.
English: If pain persists for more than 12 hours, the doctor should be consulted again.
Croatian: Ako bol potraje više od 12 sati nakon liječničkog pregleda, treba ponovo potražiti pomoć liječnika.
English: If someone is accidentally injected with this product, they must seek medical attention immediately even if only a very small amount is injected.
Croatian: Ako se netko nehotično injicira ovim veterinarsko-medicinskim proizvodom, treba potražiti hitnu medicinsku pomoć čak ako je injicirana vrlo mala količina.
English: The vaccine does not contain any live PCV2 so that it cannot cause disease.
Croatian: Cjepivo uopće ne sadrži živi PCV2 tako da ne može prouzročiti bolest.
English: PCVDs are considered to have a severe impact on pig production.
Croatian: Smatra se da PCVD ima ozbiljan učinak na proizvodnju svinja.
English: The vaccine was first studied in a number of laboratory studies in pigs.
Croatian: Djelotvornost cjepiva ispitana je prvo u nizu laboratorijskih ispitivanja u svinja.
English: Porcine circovirus vaccine (inactivated)
Croatian: Cjepivo protiv svinjskog cirkovirusa (inaktivirano)
English: Accidental injection may cause severe pain and swelling, particularly if injected into a joint or finger - this could result in the loss of the finger if prompt medical attention is not given.
Croatian: Nehotična injekcija može prouzročiti jaku bol i oticanje, naročito ako se injicira u zglob prsta, a u rijetkim slučajevima može rezultirati gubitkom zahvaćenog prsta ako nije pružena hitna medicinska pomoć.
English: The vaccine contains small amounts of a protein from PCV2.
Croatian: Cjepivo sadrži male količine proteina iz virusa PCV2.
English: The most common side effect with Porcilis PCV ID (seen in more than 1 in 10 pigs) is a short-lived local reaction with hard non-painful swellings up to 2 cm in diameter which disappear within about five weeks of vaccination.
Croatian: Najčešća nuspojava VMP-a Porcilis PCV ID (uočena u više od 1 na 10 svinja) je kratkotrajna lokalna reakcija s tvrdim bezbolnim oteklinama promjera do 2 cm koja nestaje u roku od otprilike pet tjedana nakon cijepljenja.
English: The vaccine is given using a suitable needle-free device for injection into the skin.
Croatian: Cjepivo se primjenjuje odgovarajućim uređajem bez igle predviđenim za ubrizgavanje u kožu.
English: The withdrawal period for meat from pigs treated with Porcilis PCV ID is ‘zero' days, which means that there is no mandatory waiting time.
Croatian: Razdoblje karencije za meso svinja liječenih VMP-om Porcilis PCV ID iznosi „nula” dana, drugim riječima, nema obveznog perioda čekanja.
English: When Porcilis PCV ID is given to pigs, the animals' immune system recognises the virus protein as ‘foreign' and reacts by building up an active immune response.
Croatian: Ako se Porcilis PCV ID primjenjuje u svinja, imunosni sustav životinje prepoznaje protein virusa kao „strano” tijelo i djeluje stvarajući aktivni imunosni odgovor.
English: The laboratory studies showed that the vaccine had its full effect against PCV2 by two weeks and that protection lasted 23 weeks after vaccination.
Croatian: Laboratorijskim ispitivanjima utvrđeno je kako je cjepivo dostiglo svoje potpuno djelovanje protiv virusa PCV2 nakon dva tjedna i kako je zaštita trajala 23 tjedna nakon cijepljenja.
English: PCV2 is recognised as the primary cause of post-weaning multisystemic wasting syndrome (PMWS), but is also associated with a number of other conditions collectively known as porcine circovirus disease in Europe (PCVD) e.g porcine respiratory disease complex (PRDC), enteritis, reproductive disorders.
Croatian: PCV2 je prepoznat kao primarni uzrok sindroma kržljanja odbite prasadi (SKOP), no također je povezan s brojnim drugim stanjima koja su u Europi poznata pod zajedničkim nazivom cirkovirusna bolest svinja (PCVD), primjerice kompleks svinjske respiratorne bolesti (PRDC), enteritis, reproduktivni poremećaji.
English: The European Commission granted a marketing authorisation valid throughout the EU for Porcilis PCV ID on 28 August 2015.
Croatian: Europska komisija izdala je odobrenje za stavljanje u promet koje je za VMP Porcilis PCV ID na snazi u Europskoj uniji od 28. kolovoza 2015.
English: The main measures of effectiveness were average daily weight gain in the finishing period (fattening pigs in the period prior to slaughter) and PCV2 viraemia (virus in the blood).
Croatian: Glavna mjerila djelotvornosti bila su prosječan prirast u završnom razdoblju (svinje u tovu u razdoblju prije klanja) i viremija PCV2 (prisutnost virusa u krvi).
English: PCV2 infection is widespread and nearly all pig herds are infected with PCV2.
Croatian: Infekcija PCV2 vrlo je raširena i gotovo je svako krdo svinja zaraženo virusom PCV2.
English: In all three studies average daily weight gain in the finishing period was significantly higher in the pigs vaccinated with Porcilis PCV ID compared with the non-vaccinated pigs.
Croatian: U sva tri ispitivanja prosječan dnevni prirast u završnom razdoblju bio je značajno veći u svinja cijepljenih VMP-om Porcilis PCV ID u usporedbi s necijepljenim svinjama.
English: This is a summary of the European public assessment report (EPAR) for Porcilis PCV ID.
Croatian: Ovo je sažetak europskoga javnog izvješća o ocjeni dokumentacije (EPAR) o lijeku Porcilis PCV ID.
English: The Agency's Committee for Medicinal Products for Veterinary Use (CVMP) concluded that Porcilis PCV ID's benefits are greater than its risks and recommended that it be approved for use in the EU.
Croatian: Odbor za veterinarsko-medicinske proizvode (CVMP) pri Agenciji odlučio je da koristi VMP-a Porcilis PCV ID nadmašuju s njim povezane rizike te je preporučio njegovo odobrenje za primjenu u Europskoj uniji.
English: Porcilis PCV ID is an emulsion containing mineral oil.
Croatian: Porcilis PCV ID je emulzija koja sadrži mineralno ulje.
English: Porcilis PCV ID has also been investigated in three field studies involving pig farms where PCV2 infection was present.
Croatian: Porcilis PCV ID je također ispitan u tri terenska ispitivanja koja su obuhvatila farme svinja na kojima je bio prisutan PCV2.
English: Porcilis PCV ID contains the adjuvant light mineral oil and dl-α-tocopheryl acetate to enhance the immune response.
Croatian: Porcilis PCV ID sadrži kao adjuvans blago mineralno ulje i dl-α-tokoferil acetat kako bi se pojačao imunosni odgovor.
English: It will also help to reduce the loss of daily weight gain and mortality associated with PCV2 infection.
Croatian: Također će pomoći pri smanjenju gubitka dnevnog prirasta i mortaliteta koji su povezani s infekcijom virusom PCV2.
English: This will help reduce the PCV2 viraemia, virus load in the lungs and lymphoid tissue and virus shedding.
Croatian: To će pomoći pri smanjenju viremije PCV2, virusnog opterećenja u plućima i limfoidnom tkivu kao i otpuštanja virusa.
English: Porcilis PCV ID is available as an emulsion for injection and can only be obtained with a prescription.
Croatian: Porcilis PCV ID dostupan je kao emulzija za injekciju i izdaje se samo na recept.
English: The vaccine is used to reduce viraemia (presence of the virus in the blood), virus load in the lungs and lymphoid tissues and virus shedding.
Croatian: Cjepivo se koristi za smanjenje viremije (prisutnosti virusa u krvi), virusnog opterećenja u plućima i limfoidnim tkivima te otpuštanja virusa.
English: Similarly PCV2 viraemia was significantly lower in the vaccinated pigs compared with non-vaccinated pigs.
Croatian: Slično tomu, viremija PCV2 bila je značajno niža u cijepljenih svinja nego u necijepljenih svinja.
English: Porcilis PCV ID is a veterinary vaccine against porcine circovirus type 2 (PCV2) infection in pigs.
Croatian: Porcilis PCV ID je veterinarsko cjepivo protiv infekcije svinjskim cirkovirusom tipa 2 (PVC2) kod svinja.
English: It is not intended to provide practical advice on how to use Porcilis PCV ID.
Croatian: Svrha sažetka nije davati praktične savjete o primjeni lijeka Porcilis PCV ID.
English: Porcilis PCV ID is a vaccine.
Croatian: Porcilis PCV ID je cjepivo.
English: The vaccine is also used to reduce loss of daily weight gain and mortality associated with PV2 infection.
Croatian: Cjepivo se također koristi za smanjenje gubitka dnevnog prirasta i mortaliteta koji su povezani s infekcijom virusom PCV2.
English: What is Porcilis PCV ID and what is it used for?
Croatian: Što je Porcilis PCV ID i za što se koristi?
English: Porcilis PCV ID contains the active substance porcine circovirus (PCV2) ORF2 subunit antigen.
Croatian: Porcilis PCV ID sadrži djelatnu tvar svinjski cirkovirus tip 2 (PCV 2), ORF2 subjedinični antigen.
English: Other information about Porcilis PCV ID
Croatian: Ostale informacije o Porcilis PCV ID
English: For practical information about using Porcilis PCV ID, animal owners or keepers should read the package leaflet or contact their veterinarian or pharmacist.
Croatian: Praktične informacije o primjeni VMP-a Porcilis PCV ID vlasnici životinja ili uzgajivači trebaju pročitati u uputi o VMP-u, odnosno trebaju se obratiti svojem veterinaru ili ljekarniku.
English: What are the risks associated with Porcilis PCV ID?
Croatian: Koji su rizici povezani s VMP-om Porcilis PCV ID?
English: Why is Porcilis PCV ID approved?
Croatian: Zašto je Porcilis PCV ID odobren?
English: The full EPAR for Porcilis PCV ID can be found on the Agency's website: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
Croatian: Cjeloviti EPAR za VMP Porcilis PCV ID nalazi se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports Dodatne informacije o terapiji VMP-om Porcilis PCV ID vlasnici životinja ili uzgajivači trebaju pročitati u uputi o VMP-u, odnosno trebaju se obratiti svojem veterinaru ili ljekarniku.
English: Safety information has been included in the summary of product characteristics and the package leaflet for Porcilis PCV ID, including the appropriate precautions to be followed by healthcare professionals and animal owners or keepers.
Croatian: U sažetku opisa svojstava VMP-a kao i u uputi o VMP-u Porcilis PCV ID nalaze se sigurnosne informacije, uključujući odgovarajuće mjere opreza kojih se veterinari te vlasnici životinja ili uzgajivači trebaju pridržavati.
English: The vaccine is given to fattening pigs from three weeks of age as a single injection into the skin at the side of the neck, along the back or in the hind leg. Protection against PCV 2 starts two weeks after vaccination and lasts for 23 weeks after vaccination.
Croatian: Cjepivo se primjenjuje u svinja za tov u starosti od tri tjedna i više kao jedna injekcija u kožu sa strane vrata, duž mišića leđa ili stražnje noge.
English: What benefits of Porcilis PCV ID have been shown in studies?
Croatian: Koje su koristi VMP-a Porcilis PCV ID utvrđene u ispitivanjima?
English: How does Porcilis PCV ID work?
Croatian: Kako djeluje Porcilis PCV ID?
English: How is Porcilis PCV ID used?
Croatian: Kako se koristi Porcilis PCV ID?
English: Efficib should not be used during pregnancy.
Croatian: Efficib se ne smije uzimati tijekom trudnoće.
English: If you stop taking Efficib, your blood sugar may rise again.
Croatian: Ako prestanete uzimati Efficib, razina šećera u krvi može ponovno porasti.
English: Efficib with alcohol
Croatian: Efficib s alkoholom
English: Efficib is contraindicated in patients with:
Croatian: Efficib je kontraindiciran u bolesnika:
English: The safety and efficacy of Efficib in children and adolescents from birth to < 18 years of age have not been established.
Croatian: Sigurnost i djelotvornost lijeka Efficib u djece i adolescenata od rođenja do < 18 godina nisu ustanovljene.
English: What Efficib looks like and contents of the pack
Croatian: Kako Efficib izgleda i sadržaj pakiranja
English: Other medicines and Efficib
Croatian: Drugi lijekovi i Efficib
English: What Efficib is and what it is used for What you need to know before you take Efficib How to take Efficib
Croatian: Što je Efficib i za što se koristi Što morate znati prije nego počnete uzimati Efficib Kako uzimati Efficib
English: What Efficib is and what it is used for
Croatian: Što je Efficib i za što se koristi
English: The following statements reflect the pharmacokinetic properties of the individual active substances of Efficib.
Croatian: Sljedeće izjave odražavaju farmakokinetička svojstva pojedinačnih djelatnih tvari lijeka Efficib.
English: Your doctor may ask you to stop Efficib.
Croatian: Vaš liječnik može zatražiti da prestanete s uzimanjem lijeka Efficib.
English: What Efficib contains
Croatian: Što Efficib sadrži
English: What you need to know before you take Efficib
Croatian: Što morate znati prije nego počnete uzimati Efficib
English: During treatment with Efficib, your doctor will check your kidney function at least once a year or more frequently if you are elderly and/or if you have worsening kidney function.
Croatian: Tijekom liječenja lijekom Efficib, liječnik će Vam provjeravati funkciju bubrega najmanje jedanput godišnje ili češće ako ste starija osoba i/ili ako Vam se funkcija bubrega pogoršava.
English: Your doctor will decide when you must stop and when to restart your treatment with Efficib.
Croatian: Liječnik će odlučiti kada morate prekinuti i kada ćete nastaviti s liječenjem lijekom Efficib.
English: STOP taking Efficib and contact a doctor immediately if you notice any of the following serious side effects:
Croatian: PRESTANITE uzimati Efficib i odmah se javite liječniku ako primijetite bilo koju od sljedećih ozbiljnih nuspojava:
English: Efficib contains two different medicines called sitagliptin and metformin.
Croatian: Efficib sadrži dva različita lijeka koji se zovu sitagliptin i metformin.
English: The level of digoxin in your blood may need to be checked if taking with Efficib.
Croatian: Možda će biti potrebno provjeravati razinu digoksina u Vašoj krvi ukoliko se uzima s lijekom Efficib.
English: If you need to have major surgery you must stop taking Efficib during and for some time after the procedure.
Croatian: Ako se morate podvrgnuti velikom kirurškom zahvatu, morate prestati uzimati lijek Efficib tijekom i još neko vrijeme nakon zahvata.
English: If no adequate strength of Efficib is available, individual monocomponents should be used instead of the fixed-dose combination.
Croatian: Ako nije dostupna odgovarajuća jačina lijeka Efficib, potrebno je primijeniti pojedinačne komponente zasebno umjesto fiksne kombinacije.
English: Efficib must be discontinued at the time of surgery under general, spinal or epidural anaesthesia.
Croatian: Primjena lijeka Efficib mora se prekinuti u vrijeme kirurškog zahvata pod općom, spinalnom ili epiduralnom anestezijom.